Privacy Overview
This website uses cookies to improve your experience while you navigate through the website. Out of these, the cookies that are categorized as necessary are stored on your browser as they are essential for the working of basic functionalities of the website. We also use third-party cookies that help us analyze and understand how you use this website. These cookies will be stored in your browser only with your consent. You also have the option to opt-out of these cookies. But opting out of some of these cookies may affect your browsing experience.
Always Active
Necessary cookies are absolutely essential for the website to function properly. These cookies ensure basic functionalities and security features of the website, anonymously.
Functional cookies help to perform certain functionalities like sharing the content of the website on social media platforms, collect feedbacks, and other third-party features.

No cookies to display.

Performance cookies are used to understand and analyze the key performance indexes of the website which helps in delivering a better user experience for the visitors.

No cookies to display.

Analytical cookies are used to understand how visitors interact with the website. These cookies help provide information on metrics the number of visitors, bounce rate, traffic source, etc.
Advertisement cookies are used to provide visitors with relevant ads and marketing campaigns. These cookies track visitors across websites and collect information to provide customized ads.
Other uncategorized cookies are those that are being analyzed and have not been classified into a category as yet.

Pierre Daram

1 April 2022

Pierre has over 20 years of industrial experience in Therapeutics Development from Discovery to Market Authorization in oncology and anti-infectives.
In 1996 he obtained a PhD in Molecular Biology and Biochemistry from the ENSAM of Montpelier followed with a Post graduate position at the Polytechnical School of Zurich (ETHZ).

Over the past 10 years he was dedicated to antibiotic development and has successfully conducted clinical studies in several indications such as Diabetic foot Infection, Prosthetic joint Infections, Acute Bacterial Skin and Skin Structure Infection

Prior to working for GARDP Pierre was a Global Project Leader, Associate Director Portfolio Management at Debiopharm International in charge of the anti-infective platform and Alliance Manager of several programs. He successfully secured contracts with CARB-X to expedite the development of new antibiotics targeting specific pathogens and successfully participated in strategic in-licensing activities to increase value of the Company pipeline.